Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...